APLS
Apellis Pharmaceuticals, Inc. NASDAQ$40.97
Mkt Cap $5.2B
52w Low $16.10
99.9% of range
52w High $41.00
50d MA $29.23
200d MA $25.00
P/E (TTM)
227.6x
EV/EBITDA
45.5x
P/B
13.9x
Debt/Equity
1.3x
ROE
6.0%
P/FCF
70.3x
RSI (14)
—
ATR (14)
—
Beta
-0.20
50d MA
$29.23
200d MA
$25.00
Avg Volume
5.2M
About
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-rela…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.39 | -0.47 | -20.5% | 22.13 | +1.2% | -3.2% | -2.2% | -5.3% | -6.5% | -8.9% | -20.3% | — |
| Oct 30, 2025 | AMC | 1.03 | 1.67 | +62.1% | 20.73 | +1.3% | +3.6% | -0.2% | -1.3% | -3.8% | -4.9% | +2.3% | — |
| Jul 31, 2025 | AMC | -0.44 | -0.33 | +25.0% | 22.34 | -0.4% | +2.7% | +8.6% | +8.3% | +6.2% | +8.9% | +26.1% | — |
| May 7, 2025 | AMC | -0.36 | -0.74 | -105.6% | 17.99 | -1.0% | -1.0% | -3.8% | -2.6% | -3.9% | -7.2% | +7.2% | — |
| Feb 28, 2025 | AMC | -0.37 | -0.29 | +21.6% | 25.15 | -1.4% | -4.3% | -0.4% | +3.4% | +0.7% | -0.4% | -13.0% | — |
| Nov 5, 2024 | AMC | -0.32 | -0.46 | -43.8% | 28.08 | +6.6% | +2.7% | +2.4% | +6.8% | +5.3% | +4.2% | +19.1% | — |
| Aug 1, 2024 | AMC | -0.33 | -0.28 | +15.2% | 36.00 | -0.6% | +1.6% | -5.9% | -2.5% | -6.7% | +4.6% | +7.8% | — |
| May 7, 2024 | AMC | -0.54 | -0.54 | +0.0% | 43.90 | +0.5% | -3.6% | -3.1% | -4.4% | -2.0% | -6.2% | -6.5% | — |
| Feb 27, 2024 | AMC | -0.66 | -0.73 | -10.6% | 69.35 | +1.6% | -7.6% | -10.6% | -7.9% | -6.8% | -9.9% | -15.2% | — |
| Nov 1, 2023 | AMC | -0.84 | -1.17 | -39.3% | 49.90 | +1.4% | -1.2% | -6.2% | -8.9% | -5.2% | -5.8% | +23.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 24 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $32.72 | $32.77 | +0.2% | -6.0% | -6.5% | -8.8% | -9.9% | -11.9% |
| Sep 23 | Baird | Maintains | Outperform → Outperform | — | $32.51 | $32.23 | -0.9% | +0.6% | -5.4% | -5.9% | -8.2% | -9.4% |
| Sep 20 | Needham | Maintains | Buy → Buy | — | $36.73 | $34.00 | -7.4% | -11.5% | -10.9% | -16.3% | -16.7% | -18.7% |
| Sep 20 | Mizuho | Maintains | Neutral → Neutral | — | $36.73 | $34.00 | -7.4% | -11.5% | -10.9% | -16.3% | -16.7% | -18.7% |
| Sep 13 | JP Morgan | Maintains | Overweight → Overweight | — | $36.78 | $36.29 | -1.3% | +2.3% | -1.3% | -3.4% | -3.1% | -0.1% |
| Aug 13 | JP Morgan | Maintains | Overweight → Overweight | — | $36.16 | $36.30 | +0.4% | -1.2% | -0.4% | +4.0% | +3.0% | +6.7% |
| Aug 9 | UBS | Maintains | Buy → Buy | — | $37.66 | $37.68 | +0.1% | -1.7% | -4.0% | -5.2% | -4.4% | -0.1% |
| Aug 9 | Baird | Maintains | Outperform → Outperform | — | $37.66 | $37.68 | +0.1% | -1.7% | -4.0% | -5.2% | -4.4% | -0.1% |
| Aug 9 | Wedbush | Maintains | Neutral → Neutral | — | $37.66 | $37.68 | +0.1% | -1.7% | -4.0% | -5.2% | -4.4% | -0.1% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $37.66 | $37.68 | +0.1% | -1.7% | -4.0% | -5.2% | -4.4% | -0.1% |
Recent Filings
8-K
Apellis Pharmaceuticals, Inc. -- 8-K Filing
Apellis Pharmaceuticals modified its executive separation plan to allow C-level officers, including named executives, to claim "Good Reason" severance if the company becomes a subsidiary, protecting them from losing termination benefits in an acquisition.
May 4
SC TO-T
!!! Very High
Unknown — Tender Offer
Apeilon Therapeutics shareholders have an opportunity to sell their shares at a predetermined price, suggesting potential acquisition or going-private transaction that could provide certainty versus biotech development risk.
Apr 14
8-K
Unknown — 8-K Filing
Biogen is acquiring Apellis for an upfront payment plus contingent value rights, signaling aggressive expansion into complement-driven therapies and providing Apellis shareholders a defined exit with potential earn-out upside.
Mar 31
8-K
Unknown — 8-K Filing
APLS shareholders face a 20-day tender offer deadline at a fixed price plus one contingent value right, suggesting acquisition interest that investors must evaluate against potential future upside or downside risks.
Mar 31
8-K
Apellis Pharmaceuticals, Inc. -- 8-K Filing
Apellis Pharmaceuticals' executive compensation includes change-of-control protections allowing Dolsten's RSUs and options to fully accelerate vesting upon company acquisition, incentivizing retention during potential M&A discussions.
Mar 2
Data updated apr 24, 2026 6:29pm
· Source: massive.com